B+
Bull case
20%
Probability
Target price
$7.25
Analysis reference price unavailable
Analysis 2026-01-16 · RankAlpha Sentiment AI
MDGL
MadrigalFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$2.90
Analysis reference price unavailable
Analysis 2026-01-16 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$0.73
Analysis reference price unavailable
Analysis 2026-01-16 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-01-16
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Third‑party price‑target aggregates show nominal targets far above the authoritative anchor, creating a clear valuation disconnect [#SERP-1] [#SERP-3]. Near‑term sentiment is cautious and headline‑driven around clinical and corporate‑update windows, while successful binary outcomes would produce outsized upside. This mix of high execution risk and event-driven upside underpins the current buy view with moderate confidence.
RankAlpha Sentiment AI - 2026-01-16
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-02-28eventQuarterly earnings / corporate updateHigh impact
Company quarterly report and corporate update (date estimated as quarter end; assumption noted), which can reset guidance and near-term sentiment.
2026-04-16catalystPotential late‑stage NASH readout / regulatory updateHigh impact
Estimated late‑stage clinical readout or regulatory update for resmetirom; date conservatively estimated when no firm date disclosed [#SERP-1].
2027-01-16catalystCommercial uptake / label expansion outcomesHigh impact
Outcome-driven revenue inflection from broader label/commercial adoption over the next year; modeled as long-term upside driver.
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-16 • Updated nightlySource: Internal modelMethodology